(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Impact of NIH funding reductions felt in cancer and infectious disease trials - 2Turkey key underlying issue as Israel, Greece, Cyprus hold summit
- 3Italy Brings In New Measures In 2026 To Tackle Overtourism
- 4Home Wellness Basics: Building Your Home Exercise center
- 5Chinese fossils reveal a primordial burst of animal evolution
- Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
- Pacific voyagers’ remarkable environmental knowledge allowed for long-distance navigation without Western technology
- How Deforestation Is Reshaping Mosquito-Human Contact
- Sahel coups push Africa to top of global democratic declines, report finds
- Step by step instructions to Think about Disc Rates Across Various Banks
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- Hundreds rally in West Bank against Israeli death penalty for Palestinians
- Artemis 2 astronauts see Earth in the rear-view mirror | Space photo of the day for April 3, 2026
- Figure out How to Explore Land Close to 5G Pinnacles
